0001209191-18-017715.txt : 20180307 0001209191-18-017715.hdr.sgml : 20180307 20180307161823 ACCESSION NUMBER: 0001209191-18-017715 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180305 FILED AS OF DATE: 20180307 DATE AS OF CHANGE: 20180307 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lippoldt Darin CENTRAL INDEX KEY: 0001504783 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 18673588 MAIL ADDRESS: STREET 1: C/O VOLCANO CORPORATION STREET 2: 3661 VALLEY CENTRE DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330525145 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 12780 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-03-05 0 0000914475 NEUROCRINE BIOSCIENCES INC NBIX 0001504783 Lippoldt Darin 12780 EL CAMINO REAL SAN DIEGO CA 92130 0 1 0 0 Chief Legal Officer Common Stock 2018-03-05 4 M 0 1979 18.15 A 18041 D Common Stock 2018-03-05 4 S 0 1979 88.4738 D 16062 D Non-Qualified Stock Option 18.15 2018-03-05 4 M 0 1979 18.15 D 2024-11-03 Common Stock 1979 15831 D The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $85.27 to $90.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Represents option which vests 1/4 upon anniversary of grant (11/3/2014), thereafter vesting in equal monthly installments over the following three years such that the entire award is fully vested at 11/3/2018. /s/ Darin Lippoldt 2018-03-07